Published

630. Synthetic Psilocybin (COMP360) for Chronic Active Suicidal Ideation: An Open-Label Study

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Biological Psychiatry
Date: 2025-04-09
Source: OpenAlex
DOI: 10.1016/j.biopsych.2025.02.869
PubMed: Unavailable

Authors

Scott Aaronson Tammy Miller Audrey Shoultz Bryce Lund Jeffrey LaPratt Margo Lauterbach Kim Swartz Andrew van der Vaart

Watch author

Derived topics and classifications

psilocybin Pharmacology Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

630. Synthetic Psilocybin (COMP360) for Chronic Active Suicidal Ideation: An Open-Label Study2025-04-09

Related papers

The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic ReviewJournal of Sociology Psychology & Religious Studies · 2023-11-06 Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)Current Psychology · 2024-11-21 B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult PopulationsArchives of Clinical Neuropsychology · 2024-09-12 Psychedelic Drug Therapy for Mental Disorders?Open Journal of Medical Psychology · 2023-01-01 Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test?Journal of Humanistic Psychology · 2022-08-18 A-118 Psychedelic Interventions for Neuropsychological ConditionsArchives of Clinical Neuropsychology · 2022-08-16 Developing Guidelines and Competencies for the Training of Psychedelic TherapistsJournal of Humanistic Psychology · 2017-06-29 Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of AlcoholismJournal of Humanistic Psychology · 2016-10-16